Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...
4d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback